Pen Academic Publishing   |  ISSN: 2602-4810   |  e-ISSN: 2602-4535

Derleme Makalesi | Uluslararası Fen Araştırmalarında Yenilikçi Yaklaşımlar Dergisi 2018, Cil. 2(4) 152-161

Doğal Öldürücü (Natural Killer: NK) Hücreler ve Kanser İmmunoterapisi

Ayfer Karlıtepe & Mehtap Kılıç Eren

ss. 152 - 161   |  DOI: https://doi.org/10.29329/ijiasr.2018.173.4   |  Makale No: MANU-1812-20-0001.R1

Yayın tarihi: Aralık 26, 2018  |   Okunma Sayısı: 75  |  İndirilme Sayısı: 216


Özet

Doğal öldürücü hücreler (Natural Killer: NK) birçok aktivatör ve inhibitör reseptörlere sahip olan CD3- CD56+ lenfositlerdir. NK hücrelerinin kanser tedavisine yönelik olarak otolog ve allojenik kullanımları söz konusudur. Bunun yanı sıra ticari olarak elde edilen NK hücreleri ve bazı kaynaklardan (kordon kanı ve kemik iliği hematopoietik kök hücreleri, embriyonik ve indüklenmiş pluripotent kök hücreler (IPS)) farklılaştırılarak elde edilen NK hücreleri de kanser tedavisinde kullanılmaktadır. NK hücre bazlı immünoterapinin, kanser tedavisine yönelik etkin bir tedavi yaklaşımı oluşturabileceği yapılan çalışmalar ile desteklenmektedir. Derlemede pankreas, over, prostat, akciğer, kolon ve meme kanserleri yanısıra glioma ile ilgili NK hücre bazlı immünoterapi çalışmalarına yer verilmiştir.

Anahtar Kelimeler: Doğal öldürücü hücreler, Kanser


Bu makaleye nasıl atıf yapılır?

APA 6th edition
Karlitepe, A. & Eren, M.K. (2018). Doğal Öldürücü (Natural Killer: NK) Hücreler ve Kanser İmmunoterapisi . Uluslararası Fen Araştırmalarında Yenilikçi Yaklaşımlar Dergisi, 2(4), 152-161. doi: 10.29329/ijiasr.2018.173.4

Harvard
Karlitepe, A. and Eren, M. (2018). Doğal Öldürücü (Natural Killer: NK) Hücreler ve Kanser İmmunoterapisi . Uluslararası Fen Araştırmalarında Yenilikçi Yaklaşımlar Dergisi, 2(4), pp. 152-161.

Chicago 16th edition
Karlitepe, Ayfer and Mehtap Kilic Eren (2018). "Doğal Öldürücü (Natural Killer: NK) Hücreler ve Kanser İmmunoterapisi ". Uluslararası Fen Araştırmalarında Yenilikçi Yaklaşımlar Dergisi 2 (4):152-161. doi:10.29329/ijiasr.2018.173.4.

Kaynakça
  1. Grossenbacher S K, Aguilar E G, Murphy W J, 2017, Leveraging natural killer cells for cancer immunotherapy. Immunotherapy. 9(6): 487–497. [Google Scholar]
  2. Cheng M, Chen Y, Xiao W, Sun R, Tian Z, 2013, NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol.10(3): 230–252. [Google Scholar]
  3. Mehta R, Randolph B, Daher M, Rezvani K, 2018, NK cell therapy for hematologic malignancies. International Journal of Hematology. 107:262–270. [Google Scholar]
  4. Cooper MA, Fehniger TA, Caligiuri MA, 2001, The biology of human natural killer-cell subsets. Trends Immunol. 22: 633–640. [Google Scholar]
  5. Anfossi N, Andre P, Guia S, Falk CS, Roetynck S, Stewart CA et al. 2006, Human NK cell education by inhibitory receptors for MHC class. I. Immunity. 25: 331–342. [Google Scholar]
  6. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y, 2004, Cytokines in cancer immunity and immunotherapy. Immunol Rev. 202: 275–293. [Google Scholar]
  7. McDowell K. A, Hank J. A, DeSantes K. B, Capitini C. M, Otto M, Sondel P.M, 2015, NK Cell-based Immunotherapies in Pediatric Oncology. J Pediatr Hematol Oncol. 37(2): 79–93. [Google Scholar]
  8. Mehta R, Shpall E,  Rezvani K, 2016, Cord Blood as a Source of Natural Killer Cells. doi: 10.3389/fmed..00093. [Google Scholar] [Crossref] 
  9. Cifaldi L, Locatelli F, Marasco E, Moretta L, PistoiaV, 2017, Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective. Trends in Molecular Medicine. Vol. 23, No. 12. [Google Scholar]
  10. Shailaja Kasibhatla, Thomas Brunner,Laurent Genestier, Fernando Echeverri, Artin Mahboubi, and Douglas R. Greenç, 1998, DNA Damaging Agents Induce Expression of Fas Ligand and Subsequent Apoptosis in T Lymphocytes via the Activation of NF-kB and AP-1. Molecular Cell. Vol. 1, 543–551. [Google Scholar]
  11. Ishikawa E, Tsuboi K, Saijo K, Harada H, Takano S, Nose T et al. 2004, Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res. 24: 1861–1871. [Google Scholar]
  12. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. 2002, Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 295:2097–2100. [Google Scholar]
  13. Childs R, Carlsten M, 2015, Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens. Cancer Immınotherapy. 487-498. [Google Scholar]
  14. Ning H, Lei H, Xu Y, Guan R, Venstrom J,  Lin G, Lue T,  Xin Z,  Lin C, 2014, Conversion of Adipose-Derived Stem Cells into Natural Killer-Like Cells with Anti-Tumor Activities in Nude Mice. PLoS ONE. doi:  10.1371/journal.pone.0106246. [Google Scholar] [Crossref] 
  15. Spanholt J, Tordoir M, Eissens D, Preijers P, Meer A, Joosten I, Schaap N, Witte M, Dolstra E, 2010, High Log-Scale Expansion of Functional Human Natural Killer Cells from Umbilical Cord Blood CD34-Positive Cells for Adoptive Cancer Immunotherapy. PLoS ONE. doi:  10.1371/journal.pone.0009221. [Google Scholar] [Crossref] 
  16. Luevano M,  Domogala A, Blundell M,  Jackson N,  Pedroza I,  Derniame S,  et al.  2014, Frozen Cord Blood Hematopoietic Stem Cells Differentiate into Higher Numbers of Functional Natural Killer Cells In Vitro than Mobilized Hematopoietic Stem Cells or Freshly Isolated Cord Blood Hematopoietic Stem Cell. PLOS ONE. doi:  10.1371/journal.pone.0087086. [Google Scholar] [Crossref] 
  17. Terunuma H, Deng X,  Nishino K, 2013, NK cell-based autologous immune enhancement therapy (AIET) for cancer. Journal of Stem Cells and Regenerative Medicine. 9(1): 9–13. [Google Scholar]
  18. Petta CA, Derchain SF, Alici E, Guimarães F, 2014, Up-regulation of DNAM-1 and NKp30, associated with improvement of NK cells activation after long-term culture of mononuclear cells rom patients with ovarian neoplasia. Human Immunology. 777–784. [Google Scholar]
  19. Geller MA, Knorr DA, Hermanson DA, Pribyl L, 2013, Intraperitoneal delivery of human natural killer cells for treatment of ovariancancer in a mouse xenograft model. Cytotherapy. 1297–1306. [Google Scholar]
  20. Hermanson DL, Bendzick L, Pribyl L, McCullar V, Vogel RI, 2016, Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer Stem Cells. 93-101. [Google Scholar]
  21. Castriconi R. A, Daga A, Dondero G, Zona P. L, Poliani A, Melotti F, Griffero D, Marubbi R, Spaziante et al. 2009, NK Cells Recognize and Kill Human Glioblastoma Cells with Stem Cell-Like Properties. The Journal of Immunology. 3530-539. [Google Scholar]
  22. Lee S, Kang W, Yoon Y, Jin J, Song H, Her J, Kang S, Hwang Y, et al.  2015, Natural killer (NK) cells inhibit systemic metastasis of glioblastoma cells and have therapeutic effects against glioblastomas in the brain. BMC Cancer. 15(1). [Google Scholar]
  23. Yvon E, Burga R, Fernandes R, Barese C, Nguyent T, Bollerd C, 2017, Cord blood natural killer cells expressing a dominant negativeTGF-β receptor: Implications for adoptive immunotherapy for glioblastoma. Cytotherapy. 19: 408–418. [Google Scholar]
  24. Gao P, Zhang A, Sun Z, Shan Y, 2016, Autologous natural killer cells have a therapeutic effect in advanced prostate cancer patients and can mediate cytotoxicity in vitro. Int J Clin Exp Med. 9(2):2399-2406. [Google Scholar]
  25. Mathew S, Chaudhary P, Powers S, Vishwanatha J, Mathew P, 2016, Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer cells inhibits NK cell-mediated killing through LLT1-NKRP1A (CD161) interaction. Oncotarget. Vol. 7, No. 42. [Google Scholar]
  26. Okita R, Wolf D, Yasuda K, Maeda A, Yukawa T, Saisho S, Yamaguchi K, et al. 2014,  Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell- Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells. PLoS ONE. 10(10): e0139809. [Google Scholar]
  27. Janakiram N, Mohammed A, Bryant T, Zhang Y, Brewer M, Duff A, et al. 2016, Potentiating NK cell activity by combination of Rosuvastatin and Difluoromethylornithine for effective chemopreventive efficacy against Colon Cancer. Scientific Reports. 6:37046 [Google Scholar]
  28. Shenouda M, Gillgrass A, Nham T, Aarts C, Lee D, Hassell J, et al. 2017, Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours. Breast Cancer Research. 19:76. [Google Scholar]
  29. Nham T, Poznansk S,  Fan I, Vahedi F, Shenouda M, Hogg R, Lee D, Ashkar A,2017, Ex Vivo-expanded Natural Killer Cells Derived From Longterm Cryopreserved Cord Blood are Cytotoxic Against Primary Breast Cancer Cells. J Immunotherapy. [Google Scholar]